PH12022550937A1 - Pharmaceutical composition comprising selexipag - Google Patents

Pharmaceutical composition comprising selexipag

Info

Publication number
PH12022550937A1
PH12022550937A1 PH1/2022/550937A PH12022550937A PH12022550937A1 PH 12022550937 A1 PH12022550937 A1 PH 12022550937A1 PH 12022550937 A PH12022550937 A PH 12022550937A PH 12022550937 A1 PH12022550937 A1 PH 12022550937A1
Authority
PH
Philippines
Prior art keywords
selexipag
pharmaceutical composition
diphenylpyrazin
butyloxy
isopropylamino
Prior art date
Application number
PH1/2022/550937A
Other languages
English (en)
Inventor
Alexandra Schlicker-Spain
Marc Patrik Schrader
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of PH12022550937A1 publication Critical patent/PH12022550937A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH1/2022/550937A 2019-10-23 2020-10-22 Pharmaceutical composition comprising selexipag PH12022550937A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2019078905 2019-10-23
PCT/EP2020/079698 WO2021078835A1 (en) 2019-10-23 2020-10-22 Pharmaceutical composition comprising selexipag

Publications (1)

Publication Number Publication Date
PH12022550937A1 true PH12022550937A1 (en) 2023-06-14

Family

ID=75620412

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/550937A PH12022550937A1 (en) 2019-10-23 2020-10-22 Pharmaceutical composition comprising selexipag

Country Status (15)

Country Link
US (1) US20220401441A1 (https=)
EP (1) EP4048235A1 (https=)
JP (2) JP7646646B2 (https=)
KR (1) KR20220087443A (https=)
CN (1) CN114555088A (https=)
AU (1) AU2020369912A1 (https=)
BR (1) BR112022007207A2 (https=)
CA (1) CA3154802A1 (https=)
EC (1) ECSP22040921A (https=)
IL (1) IL292354A (https=)
JO (1) JOP20220093A1 (https=)
MX (1) MX2022004882A (https=)
PE (1) PE20221455A1 (https=)
PH (1) PH12022550937A1 (https=)
WO (1) WO2021078835A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR2022005274A1 (tr) * 2022-04-05 2023-10-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Seleksi̇pag'in bi̇r kati di̇spersi̇yonunu i̇çeren bi̇r fi̇lm kapli tablet
TR2022005277A2 (tr) * 2022-04-05 2023-10-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Yaş granülasyon i̇le i̇şlenmi̇ş seleksi̇pag i̇çeren bi̇r fi̇lm kapli tablet
TR2022005273A2 (tr) * 2022-04-05 2023-10-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Seleksi̇pag i̇çeren bi̇r fi̇lm kapli tablet
TR2022020995A1 (tr) * 2022-12-28 2024-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Seleksi̇pag i̇çeren bi̇r tablet formülasyonu
CN116392491A (zh) * 2023-04-11 2023-07-07 广东省实验动物监测所 司来帕格的药物组合物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI316055B (https=) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
CN104761509A (zh) 2008-02-28 2015-07-08 日本新药株式会社 纤维化抑制剂
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
HRP20151443T1 (hr) 2008-06-23 2016-01-29 Nippon Shinyaku Co., Ltd. Terapijsko sredstvo protiv stenoze kralježniäśnog kanala
CN102065864B (zh) 2008-06-23 2012-11-21 日本新药株式会社 炎性肠病治疗剂
LT2447254T (lt) 2009-06-26 2018-01-10 Nippon Shinyaku Co., Ltd. Kristalai
WO2011024874A1 (ja) 2009-08-26 2011-03-03 日本新薬株式会社 塩基付加塩
HK1198358A1 (en) 2011-08-12 2015-04-10 Ascendis Pharma A/S Sustained release composition of prostacyclin
EP2913047B1 (en) 2012-10-29 2019-05-08 Cardio Incorporated Pulmonary disease-specific therapeutic agent
PT4331607T (pt) * 2015-12-02 2025-05-22 Nippon Shinyaku Co Ltd Composição farmacêutica sólida que contém 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi}-n-(metil-sulfonil)acetamida
JOP20190204A1 (ar) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
TW201936175A (zh) * 2018-02-21 2019-09-16 日商日本新藥股份有限公司 粒狀組合物、粒狀組合物之製造方法、及粒狀組合物之溶出性改善方法
JP2022532076A (ja) * 2019-05-06 2022-07-13 アクテリオン ファーマシューティカルズ リミテッド サルコイドーシス関連肺高血圧症の治療方法

Also Published As

Publication number Publication date
EP4048235A1 (en) 2022-08-31
ECSP22040921A (es) 2022-06-30
BR112022007207A2 (pt) 2022-07-26
JP2022553313A (ja) 2022-12-22
WO2021078835A1 (en) 2021-04-29
MX2022004882A (es) 2022-08-04
CA3154802A1 (en) 2021-04-29
CN114555088A (zh) 2022-05-27
KR20220087443A (ko) 2022-06-24
PE20221455A1 (es) 2022-09-21
JP2025074286A (ja) 2025-05-13
JP7646646B2 (ja) 2025-03-17
JOP20220093A1 (ar) 2023-01-30
AU2020369912A1 (en) 2022-04-14
US20220401441A1 (en) 2022-12-22
IL292354A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
PH12022550937A1 (en) Pharmaceutical composition comprising selexipag
PH12019502033A1 (en) Pharmaceutical composition comprising selexipag
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
MX2021004000A (es) Derivados de piperidina.
EP4512399A3 (en) Solid state forms of tafamidis and salts thereof
CY1119817T1 (el) Στερεα μοναδα δοσολογιας διασπωμενη στο στομα που περιεχει συστατικο οιστετρολης
EP4501404A3 (en) Solid pharmaceutical composition containing 2-{4-[n-(5,6-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyl)acetamide
NO20074823L (no) Rasagilin-formuleringer med forbedret innholdsensartethet
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
MX2024013464A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos
NO20082547L (no) Orale formuleringer omfattende tigecycline
ZA202107826B (en) Pharmaceutical parenteral composition of dual glp1/2 agonist
WO2019194773A3 (en) The combination comprising linagliptin and metformin
ZA202204907B (en) Orally disintegrating pharmaceutical compositions of apixaban
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها
MX2021014830A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi.
MX2019015869A (es) Nuevas formulaciones orales de belinostat.
CR20220174A (es) Composición farmacéutica que comprende selexipag
MY189372A (en) Indole derivatives
WO2019151965A3 (en) Solid oral pharmaceutical compositions comprising apixaban
GR1008804B (el) Συνθεσεις για ιατρικη χρηση οι οποιες περιλαμβανουν υαλουρονικο οξυ ή αλατα αυτου, αμινοξεα, βιταμινες, ανοργανα αλατα και αλλα συστατικα